BAY 87-2243-d8
CAS: 1227158-85-1
Ref. 3D-CZB15885
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued | ||
| 50mg | Discontinued | ||
| 100mg | Discontinued |
Product Information
- 1-Cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]piperazine
- Piperazine, 1-cyclopropyl-4-[4-[[5-methyl-3-[3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl]-1H-pyrazol-1-yl]methyl]-2-pyridinyl]-
- BAY 87-2243
BAY 87-2243-d8 is a molecule that binds to messenger RNA, preventing the synthesis of proteins. It has been shown to have anticancer properties in animal models. BAY 87-2243-d8 is currently being investigated for its effects on energy metabolism and mitochondrial membrane potential in cancer cells. The mechanism of action of this drug is not fully understood, but it may involve the inhibition of ATP production through pharmacological agents or other mechanisms.
6-Fluoro-3-indoxyl-beta-D-galactopyranoside: Rifapentine is an anti-tuberculosis drug that belongs to the class of rifamycins. It is the most active of the rifamycins for the treatment of tuberculosis. Rifapentine inhibits bacterial growth by binding to DNA dependent RNA polymerase, thereby preventing transcription and replication. The high frequency of human activity has been shown using a patch clamp technique on human
